Rivervest Venture Partners
101 S. Hanley RoadSt. Louis, MO 63105-1817
Website: rivervest.com
Firm Size
- Assets Under Management (AUM):$521 Million
- Number of Funds:10
- Employees:
- Firm Type:Venture Capital
- Focus Areas:
Software & Technology
Healthcare
Description
Rivervest Venture Partners is a venture capital firm located in St. Louis, Missouri. Founded in 2000, the firm focuses on investing in early-stage life science and healthcare companies. The team at Rivervest has extensive industry experience and expertise, allowing them to identify and support promising innovations in sectors such as biotechnology, medical devices, pharmaceuticals, and diagnostics. Rivervest takes an active approach to investing, providing strategic guidance, operational support, and industry connections to their portfolio companies. They typically invest in companies that have innovative technologies or products, a strong management team, and a clear market opportunity. The firm's investments range from seed-stage funding to later-stage rounds. Besides funding, Rivervest also contributes in helping their portfolio companies navigate regulatory and clinical hurdles, develop commercialization strategies, and attract additional capital. They bring together a network of seasoned entrepreneurs, industry partners, and scientific advisors to offer valuable insights and resources to their portfolio companies. Rivervest has a successful track record, with several notable exits and portfolio companies that have gone on to achieve significant milestones. They have invested in companies such as NeuroTherapia, VMS BioMarketing, Confluence Discovery Technologies, and GYN Oncology USA. Through their investments, Rivervest aims to support innovation and contribute to the growth of the life science industry in St. Louis and beyond.Latest News
Powered by
Mar 20, 2024: Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies
Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the close of an oversubscribed $157 million Series B financing round. The round was co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn Inc., Ysios Capital, Longwood Fund, Eight Roads Ventures, and existing founding investor Pivotal Life Sciences. Since its inception in 2019, the Company has raised over $220 million .
May 18, 2023: OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy
OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced it has been awarded a $13 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The Company concurrently raised $14 million in new funding from existing investors, led by RiverVest Venture Partners and including ARCH Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, InterVest and others.